Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: The LIBRA Trial

Diabetes Care

Volumn 37, Issue 12, 2014, Pages 3270-3278

  Retnakaran, Ravi ^a,b,c   Kramer, Caroline K ^a,b   Choi, Haysook ^a   Swaminathan, Balakumar ^a   Zinman, Bernard ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CELL PROTECTION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN RESISTANCE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; CYTOPROTECTION; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED;

EID: 84911896573     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0893     Document Type: Article

References (36)

1. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patientswith type 2 diabetesmellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012
2. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009;52:1003-1012
3. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
4. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
5. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:4206-4216
6. DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 2011;96:2354-2366
7. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-229
8. Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab 2013;305:E1398-E1407
9. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: longterm effects on β-cell function. Diabetes Obes Metab 2012;14(Suppl. 3):161-166
10. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010;12:909-915
11. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412
12. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
13. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17:819-837
14. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-4408
15. Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003;52:124-132
16. Drucker DJ. Incretin-based therapy and the quest for sustained improvements in β-cell health. Diabetes Care 2011;34:2133-2135
17. Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function. Diabetes Care 2014;37:1116-1123
18. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:65-71
19. Goldenberg R, Punthakee Z; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2013;37(Suppl. 1):S8-S11
20. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
22. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 2008;16:1901-1907
23. Retnakaran R, Qi Y, Goran MI, Hamilton JK. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 2009;26:1198-1203
24. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010;376:103-111
25. Kayaniyil S, Retnakaran R, Harris SB, et al. Prospective associations of vitamin D with β-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes 2011;60:2947-2953
26. Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 2010;33:1798-1804
27. Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 2011;34:1601-1604
28. Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 2009;58:1212-1221
29. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
30. Defronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013;62:3920-3926
31. Defronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care 2013;36:3607-3612
32. RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care 2014;37:780-788
33. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-768
34. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-2047
35. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760
36. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013;1:28-34